Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02844764 · ClinicalTrials.gov registry record · Phase 2
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip
A Phase 2 study of Osteoarthritis, sponsored by VivaTech International.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 4,000
- Enrollment target
- 1
- Study location
NCT02844764 is a Phase 2 study of Osteoarthritis that is actively recruiting participants, run by VivaTech International. The registered enrollment target is 4,000 participants, above the 788-participant average among 135 other Osteoarthritis trials with a reported enrollment target (408% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02844764, a Phase 2 study of Osteoarthritis, is actively recruiting participants, sponsored by VivaTech International.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 4,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective open-label clinical study of 50 patients to determine safety and treatment potential of autologous cell therapy for pain and inflammation associated with Osteoarthritis of the hip. Follow-up will consist of a larger sample including 4,000 patients.
Conditions Studied
Interventions
- BIOLOGICAL [StroMed + platelet rich plasma (PRP)]
Study Locations (1)
Pennsylvania
- VivaTech International, Inc. - Grove City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,000 participants |
| Start Date | 2015-07 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02844764
The ClinicalTrials.gov registry entry for NCT02844764 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 4,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 788-participant average among 135 other Osteoarthritis trials with a reported enrollment target (408% higher). The listed sponsor is VivaTech International, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteoarthritis appearing as the primary indexed condition, and to 1 intervention - of which [StroMed + platelet rich plasma (PRP)] is the first listed.
NCT02844764 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02844764 about?
NCT02844764 is a clinical study titled "Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip". This is a prospective open-label clinical study of 50 patients to determine safety and treatment potential of autologous cell therapy for pain and inflammation associated with Osteoarthritis of the hip. Follow-up will consist of a larger sample including 4,000 patients.
What is the current status of trial NCT02844764?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 4,000 participants. The study started on 2015-07. Estimated completion is 2026-08.
What conditions does trial NCT02844764 study?
This clinical trial studies the following conditions: Osteoarthritis.
What interventions are being tested in trial NCT02844764?
The interventions under investigation include: [StroMed + platelet rich plasma (PRP)] (BIOLOGICAL).
Who is sponsoring clinical trial NCT02844764?
This trial is sponsored by VivaTech International, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02844764 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Knee
RECRUITING · Phase 2
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Shoulder
RECRUITING · Phase 2
-
Platelet Rich Plasma Injections In Young And Old Human Subjects
RECRUITING · Phase 2
-
A Mobile Intervention to Reduce Pain and Improve Health-III
RECRUITING · Phase 2
-
An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint
RECRUITING · Phase 2
-
Adductor Canal Block
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.